There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ocuphire Pharma (OCUP – Research Report), Aridis Pharmaceuticals (ARDS – Research Report) and Acurx Pharmaceuticals (ACXP – Research Report) with bullish sentiments.
Ocuphire Pharma (OCUP)
In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Ocuphire Pharma, with a price target of $20.00. The company’s shares closed last Wednesday at $3.76.
According to TipRanks.com, Caufield is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ocuphire Pharma with a $20.75 average price target.
See today’s best-performing stocks on TipRanks >>
Aridis Pharmaceuticals (ARDS)
H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Aridis Pharmaceuticals today and set a price target of $10.00. The company’s shares closed last Wednesday at $1.23.
According to TipRanks.com, Bernardino is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aridis Pharmaceuticals with a $6.00 average price target.
Acurx Pharmaceuticals (ACXP)
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Acurx Pharmaceuticals, with a price target of $14.00. The company’s shares closed last Wednesday at $3.98.
According to TipRanks.com, Arce is a 5-star analyst with an average return of
Currently, the analyst consensus on Acurx Pharmaceuticals is a Moderate Buy with an average price target of $13.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on OCUP:
- Ocuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA
- Ocuphire Pharma enrolls first patient in VEGA-2 Phase 3 trial of Nyxol
- Analysts See Extravagant Gains for These 2 ‘Strong Buy’ Penny Stocks
- Ocuphire Pharma submits NDA to FDA for Nyxol
- Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Reversal of Mydriasis
